Unjoni Ewropea - Malti - EMA (European Medicines Agency)

zoetis belgium sa - Ġene live aroa imħassar escherichia coli, tip 078, strain ec34195 - immunoloġiċi għall-aves, jgħixu vaċċini batterjali - chicken; turkeys - għall-immunizzazzjoni attiva tal-brojlers-tiġieġ u l-futur saffi / min irabbi biex tnaqqas l-imwiet u l-leżjonijiet (perikardite, perihepatitis, airsacculitis) assoċjati ma ' escherichia coli serotip o78.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

zoetis belgium sa - virus tal-west nile inattivat, razza vm-2 - immunoloġiċi għall-equidae - Żwiemel - għall-immunizzazzjoni attiva ta 'żwiemel ta' sitt xhur jew akbar kontra l-marda tal-virus tal-west-nile billi tnaqqas in-numru ta 'żwiemel viraemiċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - bluetongue-virus serotype-1 antigen, bluetongue virus serotype 8 antigen - immunoloġiċi - sheep; cattle - sheepactive tilqim ta 'nagħaġ u bovini għall-prevenzjoni kontra viremja u biex tnaqqas sinjali kliniċi kkawżati mill-virus tal-bluetongue serotipi 1, 2, 4 u/ jew 8 (kombinazzjoni ta massimu 2 serotipi), l-immunizzazzjoni attiva ta' nagħaġ u bovini għall-prevenzjoni kontra viremja u biex tnaqqas sinjali kliniċi kkawżati mill-virus tal-bluetongue serotipi 1,2, 4 u/ jew 8 (kombinazzjoni ta massimu 2 serotipi), l-immunizzazzjoni attiva ta ' nagħaġ għall-prevenzjoni kontra viremja u biex tnaqqas sinjali kliniċi kkawżati mill-virus tal-bluetongue serotipi 1, 2, 4 u/jew 8 (kombinazzjoni ta massimu 2 serotipi). cattleactive tilqim ta ' baqar biex jipprevjenu viremija kkawżata mill-virus tal-bluetongue tas-serotip 1, 2, 4 u/ jew 8, u biex tnaqqas sinjali kliniċi kkawżati mill-virus tal-bluetongue serotipi meta osservati f'din l-ispeċi: serotip 1, 4 u / jew 8 (kombinazzjoni ta massimu 2 serotipi). immunizzazzjoni attiva tal-bovini għall-prevenzjoni kontra viremja ikkawżat mill-virus tal-bluetongue tas-serotip 1, 2, 4 u/ jew 8, u biex tnaqqas sinjali kliniċi kkawżati mill-virus tal-bluetongue serotipi meta osservati f'din l-ispeċi: serotip 1, 4 u / jew 8 (kombinazzjoni ta massimu 2 serotipi). immunizzazzjoni attiva ta ' nagħaġ u bovini għall-prevenzjoni kontra viremja u biex tnaqqas sinjali kliniċi kkawżati mill-virus tal-bluetongue serotipi 1, 2, 4 u/jew 8 (kombinazzjoni ta massimu 2 serotipi).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - influwenza, bniedem - vaċċini - profilassi tal-influwenza fl-anzjani (65 sena u aktar). fluad tetra għandu jintuża skond ir-rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - emorraġiku-deni, l-ebola - vaċċini - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaċċini - hexyon (dtap-ipv-hb-hib) huwa indikat għat-tilqim primarja u booster tat-trabi u toddlers minn sitt ġimgħat ta ' età kontra diphtheria, tetanus, pertussis, epatite b, poliomyelitis u invażivi mard ikkawżat minn influwenza Ħemofillika tip b (hib). l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), hepatitis b surface antigen, poliovirus (inactivated) (type-1 (mahoney strain), type-2 (mef-1 strain), type-3 (saukett strain)), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaċċini - infanrix hexa huwa indikat għall-vaċċinazzjoni primarja u booster tat-trabi kontra diphtheria, tetanus, pertussis, epatite b, poliomyelitis u mard ikkawżat minn influwenza Ħemofillika tip-b.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (mahoney strain), type 2 (mef-1 strain), type 3 (saukett strain)), hepatitis b surface antigen - hepatitis b; tetanus; immunization; whooping cough; poliomyelitis; diphtheria - vaċċini - infanrix penta huwa indikat għall-vaċċinazzjoni primarja u booster tat-trabi kontra diphtheria, tetanus, pertussis, epatite b u poliomyelitis.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunoloġiċi għall-felini, - qtates - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. Ġew murija onsets ta 'immunità 1 ġimgħa wara l-kors ta' tilqim primarju għal rinotrakeite, kaliċivirus u komponenti ta 'chlamydophila felis. it-tul ta 'l-immunità huwa ta' sena wara l-aħħar vaċċinazzjoni (mill-ġdid).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunoloġiċi għall-felini, - qtates - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. Ġew murija onsets ta 'immunità ġimgħa wara l-kors ta' tilqim primarju għal rinotrakeite, kaliċivirus, chlamydophila felis u komponenti panleucopenia. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.